Ahmed Mousa - 06 Oct 2021 Form 3 Insider Report for PIERIS PHARMACEUTICALS, INC. (PVLA)

Role
Chief Business Officer
Signature
/s/ Megan Gates, Attorney-in-Fact
Issuer symbol
PVLA
Transactions as of
06 Oct 2021
Net transactions value
$0
Form type
3
Filing time
21 Oct 2021, 17:08:51 UTC
Next filing
24 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PIRS Stock Option (right to buy) 06 Oct 2021 Common Stock 45,000 $1.59 Direct F1
holding PIRS Stock Option (right to buy) 06 Oct 2021 Common Stock 65,000 $1.99 Direct F1
holding PIRS Stock Option (right to buy) 06 Oct 2021 Common Stock 65,000 $8.56 Direct F2
holding PIRS Stock Option (right to buy) 06 Oct 2021 Common Stock 95,000 $3.09 Direct F3
holding PIRS Stock Option (right to buy) 06 Oct 2021 Common Stock 125,000 $3.15 Direct F4
holding PIRS Stock Option (right to buy) 06 Oct 2021 Common Stock 150,000 $2.50 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option has fully vested.
F2 The option vested as to 25% of the option shares on February 20, 2019 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
F3 The option vested as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
F4 The option vested as to 25% of the option shares on February 27, 2021 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
F5 The option will vest as to 25% of the option shares on March 4, 2022 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.